How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,278 results for

Myocardial Infarction Stabilization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Myocardial Rupture (Treatment)

of free-wall rupture while patients are being transferred to the OR. Previous Next: Surgical Repair In most patients, immediate surgery is necessary and should not be delayed by attempts to stabilize the patient medically. Papillary muscle rupture is generally treated with mitral valve replacement. Free-wall rupture is treated by resecting the infarcted area and closing the rupture zone with Teflon or Dacron patches or by using of biologic glues. Successful off-pump surgery (without the use (...) , Lick S, Uretsky BF. Contained myocardial rupture: a variant linking complete and incomplete rupture. Heart . 2005 Feb. 91(2):e13. . Okino S, Nishiyama K, Ando K, Nobuyoshi M. Thrombolysis increases the risk of free wall rupture in patients with acute myocardial infarction undergoing percutaneous coronary intervention. J Interv Cardiol . 2005 Jun. 18(3):167-72. . Kumar S, Kaushik S, Nautiyal A, et al. Cardiac rupture in takotsubo cardiomyopathy: a systematic review. Clin Cardiol . 2011 Nov. 34(11

2014 eMedicine.com

202. Myocardial Abscess (Treatment)

Abscess Treatment & Management Updated: Nov 07, 2018 Author: Vibhuti N Singh, MD, MPH, FACC, FSCAI; Chief Editor: Mark R Wallace, MD, FACP, FIDSA Share Email Print Feedback Close Sections Sections Myocardial Abscess Treatment Medical Care Medical treatment includes the following: Antibiotics Agents for stabilization of hemodynamic status Supportive treatment includes the following: Fluid and electrolyte balance Nutritional support Next: Surgical Care Once the diagnosis of myocardial abscess is made (...) Anticoagulation therapy, in case of metallic prosthetic valve replacement Continuing antibiotic therapy Diuretic use with CHF Antiarrhythmic therapy for postoperative arrhythmias Aggressive antibiotic prophylaxis prior to minor surgeries Previous Next: Further Inpatient Care Aggressive postoperative supportive therapy in patients with myocardial abscess includes the following: Agents for stabilization of hemodynamics Fluid and electrolyte balance Nutrition (parenteral or enteral) Continuation of antibiotic

2014 eMedicine.com

203. Myocardial Ischemia (Treatment)

. One study demonstrated a significant reduction of symptomatic myocardial ischemia in patients with unstable angina or non–Q-wave infarction with the administration of a statin during the early acute phase. In a study of 10,001 patients with stable coronary artery disease, an aggressive cholesterol-lowering approach with atorvastatin 80 mg daily (mean cholesterol level of 77 mg/dL) compared to a less-aggressive approach with atorvastatin 10 mg daily (mean cholesterol level of 101 mg/dL) resulted (...) in a 2.2% absolute reduction and a 22% relative reduction in the occurrence of a first major cardiovascular event (defined as death from coronary heart disease; nonfatal, non–procedure-related myocardial infarction; resuscitation from cardiac arrest; or fatal or nonfatal stroke). [ ] This occurred with a greater incidence of elevated aminotransferase levels with the aggressive cholesterol-lowering approach (1.2% vs 0.2%, p < 0.001). Some triglyceride-rich lipoproteins, including partially degraded very

2014 eMedicine.com

204. Myocardial Abscess (Follow-up)

Abscess Treatment & Management Updated: Nov 07, 2018 Author: Vibhuti N Singh, MD, MPH, FACC, FSCAI; Chief Editor: Mark R Wallace, MD, FACP, FIDSA Share Email Print Feedback Close Sections Sections Myocardial Abscess Treatment Medical Care Medical treatment includes the following: Antibiotics Agents for stabilization of hemodynamic status Supportive treatment includes the following: Fluid and electrolyte balance Nutritional support Next: Surgical Care Once the diagnosis of myocardial abscess is made (...) Anticoagulation therapy, in case of metallic prosthetic valve replacement Continuing antibiotic therapy Diuretic use with CHF Antiarrhythmic therapy for postoperative arrhythmias Aggressive antibiotic prophylaxis prior to minor surgeries Previous Next: Further Inpatient Care Aggressive postoperative supportive therapy in patients with myocardial abscess includes the following: Agents for stabilization of hemodynamics Fluid and electrolyte balance Nutrition (parenteral or enteral) Continuation of antibiotic

2014 eMedicine.com

205. Myocardial Ischemia (Follow-up)

. One study demonstrated a significant reduction of symptomatic myocardial ischemia in patients with unstable angina or non–Q-wave infarction with the administration of a statin during the early acute phase. In a study of 10,001 patients with stable coronary artery disease, an aggressive cholesterol-lowering approach with atorvastatin 80 mg daily (mean cholesterol level of 77 mg/dL) compared to a less-aggressive approach with atorvastatin 10 mg daily (mean cholesterol level of 101 mg/dL) resulted (...) in a 2.2% absolute reduction and a 22% relative reduction in the occurrence of a first major cardiovascular event (defined as death from coronary heart disease; nonfatal, non–procedure-related myocardial infarction; resuscitation from cardiac arrest; or fatal or nonfatal stroke). [ ] This occurred with a greater incidence of elevated aminotransferase levels with the aggressive cholesterol-lowering approach (1.2% vs 0.2%, p < 0.001). Some triglyceride-rich lipoproteins, including partially degraded very

2014 eMedicine.com

206. Myocardial Rupture (Follow-up)

of free-wall rupture while patients are being transferred to the OR. Previous Next: Surgical Repair In most patients, immediate surgery is necessary and should not be delayed by attempts to stabilize the patient medically. Papillary muscle rupture is generally treated with mitral valve replacement. Free-wall rupture is treated by resecting the infarcted area and closing the rupture zone with Teflon or Dacron patches or by using of biologic glues. Successful off-pump surgery (without the use (...) , Lick S, Uretsky BF. Contained myocardial rupture: a variant linking complete and incomplete rupture. Heart . 2005 Feb. 91(2):e13. . Okino S, Nishiyama K, Ando K, Nobuyoshi M. Thrombolysis increases the risk of free wall rupture in patients with acute myocardial infarction undergoing percutaneous coronary intervention. J Interv Cardiol . 2005 Jun. 18(3):167-72. . Kumar S, Kaushik S, Nautiyal A, et al. Cardiac rupture in takotsubo cardiomyopathy: a systematic review. Clin Cardiol . 2011 Nov. 34(11

2014 eMedicine.com

207. The effect of ballooning following carotid stent deployment on hemodynamic stability. (PubMed)

on the occurrence of hemodynamic instability, adjusting for patient's age, sex, hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, recent myocardial infarction, previous carotid endarterectomy, high-risk status, and symptomatic status.A total of 103 (51 men and 52 women) patients underwent placement of a unilateral carotid stent between 2005 and 2012 at our institution. All patients underwent prestent dilatation. However, 70% (n = 72) underwent PSB whereas 30% (n = 31) did not. PSB (...) was a significant predictor of hemodynamic depression (odds ratio [OR], 3.8; 95% confidence interval, 1.3-11; P < .01). Symptomatic status, recent myocardial infarction, hyperlipidemia, and coronary artery disease were associated with a length of stay exceeding 24 hours postoperatively (OR, 6.6; P < .01, OR, 6.1; P < .01, OR, 5.4; P = .04, and OR, 9.3; P < .01, respectively). At follow-up, 97% (83/86) stents were patent. Two stent stenoses occurred in the group that received PSB, while one stent stenosis

Full Text available with Trip Pro

2013 Journal of Vascular Surgery

208. Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial New York Heart Association class II-IV congestive heart failure (serious cardiac arrhythmia requiring medication) Myocardial infarction or unstable angina =< 6 months prior to registration Congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias Clinically significant peripheral vascular disease (...) Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study

2013 Clinical Trials

209. Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD

Newly diagnosed, untreated, angiographically documented choroidal neovascularization (CNV) lesion Key Exclusion Criteria: Stroke or myocardial infarction less than 3 Months prior to study entry Active injection or inflammation of either eye at the time of study entry Any type of systemic disease (or received treatment for it), including any medical condition (controlled or uncontrolled) that were to be expected to progress, recur, or change to an extent which could bias the assessment (...) Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2013 Clinical Trials

210. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study.

STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY (STABILITY) trial.Detailed individual data on CV risk factors were obtained before randomization in 15,828 patients with chronic coronary heart disease (CHD) from 39 countries on five continents. Subjects had a history of myocardial infarction, prior coronary revascularization, or multi-vessel CHD without revascularization and at least one additional CV risk factor. The majority were taking a statin (97%), antiplatelet therapy (96 (...) Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. There is limited contemporary data on achievement of risk factor goals for secondary prevention of cardiovascular (CV) disease from countries in many regions of the world. This report describes the global and regional prevalence of CV risk factors and use of preventive medications at baseline in participants in the ongoing

2013 European journal of preventive cardiology

211. Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Heart Association (NYHA) criteria, or myocardial infarction within 6 months Any serious or uncontrolled concomitant disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study Patient has known chronic liver disease, e.g. diagnosis of chronic active hepatitis or cirrhosis Major surgery within 21 days of study treatment; minor surgery within 2 weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered (...) Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning

2012 Clinical Trials

212. A Pilot Study to Evaluate the Safety and Efficacy of the Apica Access, Stabilization and Closure (ASCâ„¢) Device

Device Device: Apica Cardiovascular ASC Access, Stability and Closure Device Access, stabilisation and closure of trans-apical approach for TAVI Other Name: Apica Cardiovascular, ASC Outcome Measures Go to Primary Outcome Measures : Access safety [ Time Frame: Within 2 hours from initial skin incision ] Observation of no myocardial tearing on entry of the device Closure safety [ Time Frame: Within 2 hours from initial skin incision ] Observation of no acute post-procedural bleeding or pericardial (...) or serious, irreversible morbidity exceeded 50%. Exclusion Criteria: Subjects will be selected in accordance with the investigating centers standard operating procedures for TAVI subject selection and treatment. The following TAVI exclusion criteria shall apply: Evidence of an acute myocardial infarction < 1 month before the intended treatment Aortic valve is a congenital unicuspid or bicuspid valve; or is non-calcified Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant

2012 Clinical Trials

213. Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer

requiring staging) must be performed within 35 days prior to the start of therapy No serious medical conditions such as myocardial infarction within 6 months prior to entry, congestive heart failure, unstable ventricular arrhythmia, uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled psychotic disorders, serious infections, active peptic ulcer disease, psychiatric illness, or any other medical conditions that might be aggravated by treatment or limit compliance Currently, no active (...) Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies

2012 Clinical Trials

214. Remote ischemic preconditioning impairs ventricular function and increases infarct size after prolonged ischemia in the isolated neonatal rabbit heart. (PubMed)

Remote ischemic preconditioning impairs ventricular function and increases infarct size after prolonged ischemia in the isolated neonatal rabbit heart. Remote ischemic preconditioning (rIPC) reduces myocardial injury in adults and children undergoing cardiac surgery. We compared the effect of rIPC in adult and neonatal rabbits to investigate whether protection against ischemia-reperfusion injury can be achieved in the newborn heart by (1) in vivo rIPC and (2) dialysate from adult rabbits (...) undergoing rIPC.Isolated hearts from newborn and adult rabbits were randomized into 3 subgroups (control, in vivo rIPC, and dialysate obtained from adult, remotely preconditioned rabbits). Remote preconditioning was induced by four 5-minute cycles of lower limb ischemia. Left ventricular (LV) function was assessed using a balloon-tipped catheter, glycolytic flux by tracer kinetics, and infarct size by tetrazolium staining. Isolated hearts underwent stabilization while perfused with standard Krebs

Full Text available with Trip Pro

2013 Journal of Thoracic and Cardiovascular Surgery

215. Endoscopic Time-Lapse Imaging of Immune Cells in Infarcted Mouse Hearts. (PubMed)

Endoscopic Time-Lapse Imaging of Immune Cells in Infarcted Mouse Hearts. High-resolution imaging of the heart in vivo is challenging owing to the difficulty in accessing the heart and the tissue motion caused by the heartbeat.Here, we describe a suction-assisted endoscope for visualizing fluorescently labeled cells and vessels in the beating heart tissue through a small incision made in the intercostal space.A suction tube with a diameter of 2 to 3 mm stabilizes the local tissue motion safely (...) and effectively at a suction pressure of 50 mm Hg. Using a minimally invasive endoscope integrated into a confocal microscope, we performed fluorescence cellular imaging in both normal and diseased hearts in live mice for an hour per session repeatedly over a few weeks. Real-time imaging revealed the surprisingly rapid infiltration of CX3CR1(+) monocytes into the injured site within several minutes after acute myocardial infarction.The time-lapse analysis of flowing and rolling (patrolling) monocytes

Full Text available with Trip Pro

2013 Circulation Research

216. Effects of L-NAME on coronary blood flow, infarct size and the extent of the no-reflow phenomenon. (PubMed)

Effects of L-NAME on coronary blood flow, infarct size and the extent of the no-reflow phenomenon. NOS inhibitors are a potential treatment for patients with cardiogenic shock during acute myocardial infarction. Despite hemodynamic efficacy, their effects on the extent of myocardial infarction (MI) and the no-reflow phenomenon (NRP) have not been clarified.Sixteen pigs underwent occlusion of the mid left anterior descending coronary artery for 1h followed by reperfusion for 2h. Coronary blood (...) and the control group.L-NAME administration started immediately before and maintained throughout reperfusion has no effect on NRP and MI size. L-NAME might stabilize patients with post-MI cardiogenic shock without adverse effects on infarct size.Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

2013 International journal of cardiology

217. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV) (PubMed)

Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV) This study evaluated the effectiveness and safety of beta-blockers and statins for the prevention of perioperative cardiovascular events in intermediate-risk patients undergoing noncardiovascular surgery.Beta-blockers and statins reduce perioperative cardiac events in high-risk (...) patients undergoing vascular surgery by restoring the myocardial oxygen supply/demand balance and/or stabilizing coronary plaques. However, their effects in intermediate-risk patients remained ill-defined.In this randomized open-label 2 x 2 factorial design trial 1066 intermediate cardiac risk patients were assigned to bisoprolol, fluvastatin, combination treatment, or control therapy before surgery (median: 34 days). Intermediate risk was defined by an estimated risk of perioperative cardiac death

2009 EvidenceUpdates Controlled trial quality: predicted high

218. Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.

imaging study was processed and read independently by 3 technologists. Mean heart/mediastinum (H/M) ratio difference (with 95% confidence interval [CI]) was used as the measure of test stability. Secondary Outcome Measures : To Assess the Test-retest Reproducibility of Iobenguane I 123 Injection Myocardial Uptake on Planar Imaging at 15 Minutes Following Administration of AdreView (Iobenguane I 123 Injection) [ Time Frame: 15 minutes post administration of 2 dosing within an interval of 5 to 14 days (...) to enrollment into the study. The participant had received defibrillation either external or via an implantable cardioverter defibrillator (ICD), anti-tachycardia pacing, or cardioversion to treat an arrhythmic event in the previous 90 days. The participant had a cardiac revascularization, insertion of an ICD, or acute myocardial infarction within 30 days before study entry. The participant used any of the following medications: Amitriptyline and derivatives, imipramine and derivatives, other

2013 Clinical Trials

219. HFR A-equilibrium on Cardiovascular Stability

less than 2 ml/min/1.73 m2 native fistula or central venous catheter with blood flow rate greater than 250 ml/min Exclusion Criteria: Life expectancy less than 1 year solid active neoplasm pregnancy major event in the previous 3 months (ictus, myocardial infarction, cachexia) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor (...) HFR A-equilibrium on Cardiovascular Stability HFR A-equilibrium on Cardiovascular Stability - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. HFR A-equilibrium on Cardiovascular Stability (AIMS) The safety

2011 Clinical Trials

220. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. (PubMed)

Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. To investigate growth differentiation factor (GDF)-15 at hospital discharge for assessment of the risk of death, recurrent myocardial infarction (MI), and congestive heart failure, and to determination of whether these risks can be modified by statins.GDF-15 is a transforming growth factor-β-related cytokine induced in response to tissue injury

Full Text available with Trip Pro

2011 Arteriosclerosis, thrombosis, and vascular biology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>